Clinical Trial Update: Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Rituximab with high-dose chemotherapy in patients with poor-prognosis Non-Hodgkin's lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Lymphoma, Non-Hodgkin's | Phase 2 | Status: TERMINATED